Guest Post: Rapid Effectiveness Assessment Process Could Shape HTA in Eastern Europe

This article was provided by Richard Staines of APM Health Europe from its coverage of the recent Health Technology Assessment World conference in London. A rapid European effectiveness assessment process comparing new drugs to standard of care could provide key data for local health technology assessment (HTA) in smaller European countries, experts have been told. However, Wim Goettsch, project leader …

NICE chief exec questions real costs of R&D

In a letter to UK newspaper The Times, the chief executive of the National Institute for Health and Care Excellence (NICE) has challenged the real costs of pharmaceutical research and development. Sir Andrew Dillon, who has headed up the UK health technology assessment (HTA) body since 1999, was responding to a comment piece by the Times' business editor, Ian King, …

Guest post: How often is PRO data being used in health technology assessments?

      *This post was originally posted on the Context Matters blog* Context Matters will be exhibiting at Health Technology Assessment World Europe this December in London.  Join us at the 6th annual policy forum for the industry where all the major HTA agencies across the world and leading pharmaceutical companies discuss the challenges in obtaining market access.   …

Download: HTA and Value of Rare Diseases Drugs Presentation

This is your chance to download the free presentation entitled HTA and Value of Rare Diseases Drugs. It's an industry perspective by Pierrick Rollet, Vice President, Global Market Access, Rare Diseases, GSK Rare Diseases. Pierrick spoke at last year's Health Technology Assessment World Europe conference and his presentation was a great success. If you are interested in this presentation then …